Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 120

1.

Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life.

Chaigne B, Finckh A, Alpizar-Rodriguez D, Courvoisier D, Ribi C, Chizzolini C; Swiss Clinical Quality Management Program For Rheumatoid Arthritis.; Swiss Systemic Lupus Erythematosus Cohort Study Group..

Qual Life Res. 2017 Mar 11. doi: 10.1007/s11136-017-1534-4. [Epub ahead of print]

PMID:
28285445
2.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JM, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Mar 6. pii: annrheumdis-2016-210715. doi: 10.1136/annrheumdis-2016-210715. [Epub ahead of print]

PMID:
28264816
3.

The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis.

Alpizar-Rodriguez D, Brulhart L, Mueller RB, Möller B, Dudler J, Ciurea A, Walker UA, Von Mühlenen I, Kyburz D, Zufferey P, Mahler M, Bas S, Gascon D, Lamacchia C, Roux-Lombard P, Lauper K, Nissen MJ, Courvoisier DS, Gabay C, Finckh A.

Clin Rheumatol. 2017 Mar;36(3):677-682. doi: 10.1007/s10067-017-3547-3.

PMID:
28110385
4.

Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA).

Iannone F, Courvoisier DS, Gottenberg JE, Hernandez MV, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X, Choquette D, Finckh A.

Clin Rheumatol. 2016 Dec 14. [Epub ahead of print]

PMID:
27966068
5.

Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM).

Mueller RB, Reshiti N, Kaegi T, Finckh A, Haile SR, Schulze-Koops H, Schiff M, Spaeth M, von Kempis J; SCQM physicians..

Clin Rheumatol. 2017 Jan;36(1):59-66. doi: 10.1007/s10067-016-3468-6.

PMID:
27838788
6.

The role of female hormonal factors in the development of rheumatoid arthritis.

Alpízar-Rodríguez D, Pluchino N, Canny G, Gabay C, Finckh A.

Rheumatology (Oxford). 2016 Sep 29. pii: kew318. [Epub ahead of print] Review.

PMID:
27686101
7.

Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study.

Courvoisier DS, Alpizar-Rodriguez D, Gottenberg JE, Hernandez MV, Iannone F, Lie E, Santos MJ, Pavelka K, Turesson C, Mariette X, Choquette D, Hetland ML, Finckh A.

EBioMedicine. 2016 Sep;11:302-306. doi: 10.1016/j.ebiom.2016.08.024.

8.

Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.

Choy E, Aletaha D, Behrens F, Finckh A, Gomez-Reino J, Gottenberg JE, Schuch F, Rubbert-Roth A.

Rheumatology (Oxford). 2016 Aug 21. pii: kew271. [Epub ahead of print] Review.

PMID:
27550301
9.

Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences.

Finckh A, Escher M, Liang MH, Bansback N.

Curr Rheumatol Rep. 2016 Aug;18(8):51. doi: 10.1007/s11926-016-0598-4. Review.

PMID:
27402108
10.

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.

Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, Strangfeld A, Zink A, Mariette X, Finckh A, Canhao H, Iannone F, Zavada J, Morel J, Gottenberg JE, Hyrich KL, Listing J.

Ann Rheum Dis. 2017 Feb;76(2):386-391. doi: 10.1136/annrheumdis-2016-209285.

11.

[Reactive arthritis: inflammation or true infection?].

Finckh A.

Rev Med Suisse. 2016 Mar 9;12(509):503-6. French.

PMID:
27089639
12.

The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.

Nissen MJ, Ciurea A, Bernhard J, Tamborrini G, Mueller R, Weiss B, Toniolo M, Exer P, Gabay C, Finckh A; physicians of the Swiss Clinical Quality Management Cohort..

Arthritis Rheumatol. 2016 Sep;68(9):2141-50. doi: 10.1002/art.39691.

PMID:
27015429
13.

Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative.

Baillet A, Gossec L, Carmona L, Wit Md, van Eijk-Hustings Y, Bertheussen H, Alison K, Toft M, Kouloumas M, Ferreira RJ, Oliver S, Rubbert-Roth A, van Assen S, Dixon WG, Finckh A, Zink A, Kremer J, Kvien TK, Nurmohamed M, van der Heijde D, Dougados M.

Ann Rheum Dis. 2016 Jun;75(6):965-73. doi: 10.1136/annrheumdis-2016-209233.

14.

Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.

Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X, Finckh A.

Arthritis Rheumatol. 2016 Jun;68(6):1346-52. doi: 10.1002/art.39595.

PMID:
26815727
15.

Low pre-treatment B-cell counts are not a risk factor of infection in patients treated with rituximab for autoimmune diseases: An observational study.

Lazarou I, Finckh A, Fischer L, Ribi C, Gascon D, Seebach JD, Guerne PA.

Joint Bone Spine. 2016 Mar;83(2):191-7. doi: 10.1016/j.jbspin.2015.05.012.

PMID:
26677998
16.

The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries.

Finckh A, Neto D, Iannone F, Loza E, Lie E, van Riel P, Hetland ML, Pavelka K, Gottenberg JE, Canhão H, Mariette X, Turesson C.

RMD Open. 2015 Apr 30;1(1):e000040. doi: 10.1136/rmdopen-2014-000040.

17.

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.

Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, Kaya G, Krähling V, Kwilas S, Lemaître B, Matthey A, Silvera P, Becker S, Fast PE, Moorthy V, Kieny MP, Kaiser L, Siegrist CA; VSV-Ebola Consortium..

Lancet Infect Dis. 2015 Oct;15(10):1156-66. doi: 10.1016/S1473-3099(15)00154-1.

PMID:
26248510
18.

Inflammatory Articular Disease in Patients with Inflammatory Bowel Disease: Result of the Swiss IBD Cohort Study.

Ditisheim S, Fournier N, Juillerat P, Pittet V, Michetti P, Gabay C, Finckh A; Swiss IBD Cohort Study Group..

Inflamm Bowel Dis. 2015 Nov;21(11):2598-604. doi: 10.1097/MIB.0000000000000548.

PMID:
26244648
20.

Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.

Gabay C, Riek M, Scherer A, Finckh A; SCQM collaborating physicians..

Rheumatology (Oxford). 2015 Sep;54(9):1664-72. doi: 10.1093/rheumatology/kev019.

PMID:
25922549

Supplemental Content

Loading ...
Support Center